Abstract Trachoma is a neglected disease and also the world's leading infectious cause of blindness. It causes misery, dependency and is a barrier to development. Trachoma is controlled by a WHO-endorsed integrated strategy of surgery for trichiasis, antibiotic therapy, facial cleanliness and environmental improvement, which is known by the acronym SAFE. The strategy is based on evidence from field trials and is continually being refined by operational research that informs national policy and planning; the strategy has affected both programme delivery and implementation. As a result of the findings of operational research, surgery is now frequently conducted by paramedics in communities rather than by ophthalmologists in hospitals; yearly mass distribution of a single oral dose of azithromycin has replaced the use of topical tetracycline; and the promotion of better hygiene, face-washing and the use of latrines are used to reduce transmission. Those who implement programmes have been equal partners in conducting operational research thus reducing the "know-do" gap and minimizing the lag that often exists between the completion of trials and putting their results into practice. Operational research has become a part of practice. Although there are still many questions without answers, national programme coordinators have a reasonable expectation that trachoma control programmes based on SAFE will work. Voir page 617 le résumé en français. En la página 618 figura un resumen en español.
Introduction
Trachoma, caused by ocular infection with Chlamydia trachomatis, is the world's leading infectious cause of blindness. 1 Repeated infection causes inflammation and scarring of the conjunctival lining of the upper eyelid, which distorts the lid margin and causes the lashes to touch the surface of the eye (trichiasis). In add d dition to disabling discomfort, constant abrasion of the cornea causes physical damage that leads eventually to corneal opacification and blindness.
Trachoma affects the most margind d alized and disadvantaged populations in 55 endemic countries. 2 More than a million people have become blind from trachoma, and about 10 million are in imminent danger of going blind from trichiasis. Vaccine trials conducted in the 1960s were unsuccessful, and during the subsequent three decades trachoma was almost forgotten. This neglect was largely due to the lack of interventions of proven efficacy. In the early 1990s it was demonstrated that a single oral dose of azithromycin was as effective as the previously recommended (but seldom used) regimen of 6 weeks of daily topical application of tetracycline .618 ‫صفحة‬ ‫يف‬ ‫بالعربية‬ ‫امللخص‬ ‫عىل‬ ‫االطالع‬ ‫ميكن‬ ointment to treat ocular infection with C. trachomatis. 3 In light of these results, the sponsor of the trial, Joseph Cook of the Edna McConnell Clark Foundation, and leading trachoma researchers end d couraged Pfizer, the manufacturer of azithromycin, to support further studies to examine the efficacy and effectiveness of providing mass treatment to control trachoma; they also encouraged Pfizer to donate the drug to trachoma control programmes. In 1998 the foundation and Pfizer established the International Trachoma Initiative. Countries eligible for donations of the drug are those that satisfy the initiative's expert committee and board that:
• they have a prevalence of active trad d choma exceeding the WHO threshd d old for intervention (considered to be a prevalence of >10% trachomatous inflammation, follicular, [known as grade TF] among children aged 1-9 years); • they are willing to operationalize the full SAFE strategy; and • they have a realistic plan for handling and distributing azithromycin. Fig. 2 and Fig. 3 ). In this way new techniques and practices are shared and translated into policy and practice without delay. Advocacy by WHO and the nongovernmental development ord d ganizations through these meetings has raised the level of awareness of trachoma in endemic countries and enabled local resources to be mobilized. The strategy for trachoma control promoted by all these organizations is the integrated strategy known as SAFE; this strategy aims both to treat and pred d vent the disease. SAFE stands for surgery for trichiasis, antibiotic therapy, facial cleanliness and environmental change. It was based on the results of the best research from the field, and it is modid d fied in the light of ongoing operational research, which is frequently conducted in partnership with implementing agend d cies. Operational research has been used to bridge the "know-do" gap and translate knowledge into action. This paper describes the process by which the evidence base for trachoma control using the SAFE strategy has been developed and why there is a good expectation that it will be effective (Box 1).
Surgery for trachomatous trichiasis
Approximately 10 million people have trachomatous trichiasis. Trachoma cond d trol programmes need to prioritize treatd d ment of these individuals because if the disease is left untreated they are at high risk of developing irreversible blinding corneal opacification. 5, 6 Lid surgery for trachomatous trichiasis is believed to reduce the risk of progressive corneal opacification and blindness. 7, 8 There is a growing body of operational research that has guided trachoma control programmes as they implement the initial surgical component of the SAFE strategy.
Indications for surgery vary between control programmes. Some advocate early surgery -when one or more lashes touch the eye -while others practice epilation until more severe trachomatous trichiasis develops. Data from the Gambia on the natural hisd d tory of trachomatous trichiasis suggest that disease progression can be quite swift. 5 Therefore, where contact with eyedcare services is infrequent, surgery for mild disease is probably appropriate. In addition, surgery for mild disease is technically easier and is likely to have a better outcome. 8 Several different surgid d cal procedures are in use. A randomized controlled trial (RCT) in Oman comd d pared several alternatives and identified bilamellar tarsal rotation as having the lowest rate of recurrence of trachomatous trichiasis. 7 WHO endorses this operad d tion for trachoma control programmes. This surgery and posterior lamellar tarsal rotation were formally compared in an RCT in Ethiopia. 9 The study found no difference in the recurrence rate of trichiasis three months after surgery; however, longdterm followdup data are still needed.
Most countries where trachoma is endemic have an insufficient number of ophthalmologists to deliver the volume of surgery required. Therefore, many programmes train nurses and other parad d medical staff to perform eyelid surgery. An RCT from Ethiopia found no differd d ence in the outcome of trachomatous trichiasis surgery performed by trained nurses when compared with surgery performed by ophthalmologists. 10 A retrospective review of trachomatous trichiasis surgery in Morocco found that patients operated on by nurses had significantly fewer recurrences of trichiasis than patients operated on by ophthalmologists, possibly because ophthalmologists tended to operate on more difficult cases. 11 These studies support the pragmatic decision to train nondophthalmologists in trachomatous trichiasis surgery.
In many endemic settings accepd d tance of surgery is low. Barriers to the uptake of surgery include a lack of knowledge, the cost, fear, inaccessibility and being too busy. 12 Inaccessibility is a consistent barrier, and villagedbased surgery might be expected to improve uptake. In a community RCT in the Gambia the acceptance rate for surgery was 45% higher when the surgery was villagedbased than when it was health centredbased (although the difference did not reach statistical significance). 13 There was no difference in rates of recurd d rent trichiasis or complications between those who had surgery in the village and those who had it at the health centre. The cost to the patient was significantly lower for those who had villagedbased surgery.
Trichiasis recurrence is reported to vary between about 20% at one year and 62% by three years. 7, 8, [14] [15] [16] Several factors may contribute to recurrence. The choice of procedure is important. Interdsurgeon variability also occurs, emphasizing the importance of implementing ongod d ing audit to identify surgeons in need of additional training and support. 8, 14 Conjunctival infection with C. trachom m matis and other bacteria may promote ongoing inflammation and progressive scarring. 8 Given the disappointingly high rates of recurrence there is a pressing need to develop strategies to improve the longd term outcome of surgery to ensure that surgical services most effectively minid d mize the incidence of blindness caused by trachoma.
Antibiotics
A Cochrane review of the effect of antibid d otics on trachoma showed that although antibiotics seem to lower the relative risk both of disease and infection at three months and 12 months after treatment, data are also consistent with the conclud d sion that antibiotics have no effect on an individual case. 18 However, trachoma control prod d grammes use antibiotics for two reasons: first, to treat individual infections (and thereby hopefully reduce each patient's risk of developing pathologically signifid d cant conjunctival scarring), and, second, to limit transmission of infection to others. Because many people who are infected do not have signs of disease on examination, 19 mass treatment of all ind d dividuals living in a community seems a rational approach wherever the prevad d lence of trachoma is high. Supervised mass treatment with topical tetracycline of populations in trachomadendemic areas is logistically difficult since tetrad d cycline must be applied twice a day for many weeks to be effective. Unsuperd d vised treatment is believed to be inefd d fective because adherence to the treatd d ment regimen is often poor. 20 For these reasons, the discovery that singleddose oral azithromycin was as effective for an individual case as supervised topical tetracycline 3 represented a significant breakthrough.
Subsequently, the "azithromycin in control of trachoma" trial was undertaken to compare the impact of azithromycin with tetracycline when given to whole communities. 21 Pairs of villages in the Gambia, Egypt and the United Republic of Tanzania were matched according to the prevalence of active trachoma among children. For both treatments villaged wide prevalences of infection at one year were substantially lower than at baseline. The reduction in infection prevalence was greater with azithromycin than with tetracycline, although the difference was not significant. 21 This study established the effid d cacy 21 and safety 22 of mass treatment with azithromycin. It was the basis for the launch of the Pfizer donation prod d gramme, and it invigorated the GET 2020 alliance. A mathematical model of the effect of periodic antibiotic treatment on clinical signs of disease predicted that to eliminate trachoma, mass treatd d ment would be needed at least every six months in hyperdendemic areas and at least every 12 months in mesodendemic areas; 23 longitudinal data were needed to confirm or modify the treatment recomd d mendations that were based on these findings and routinely used by national programmes.
Several studies have used quantitad d tive polymerase chain reaction to study the epidemiology of ocular C. trachom m matis infection in untreated communid d ties and to provide empirical evidence of the impact of mass treatment with azithromycin. These studies have shown that:
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• This last point presents a particular difficulty for programme managers. While on the one hand azithromycin is well tolerated by recipients and donated by Pfizer, it is wasted treating nondexistent infections when it could be directed towards those with actual infections, if they could be identified. A rapid lowdcost fielddbased test for C. trachomatis would be extremely useful to help programmes determine which communities need to be offered antibiotics. Early trials of a candidate dipstick assay have shown promising results. Distributing the drug requires allocating resources that could be used in other ways; in Ethiopia an assessment of the utility of saving both costs and drug by determining whether ocular C. trachomatis can be eliminated from a community by treating only children is ongoing.
Facial cleanliness and envi--ronmental improvement
The "F" and "E" components of the SAFE strategy (facial cleanliness and environmental improvement) are fred d quently described together since their Box 1. Why has the SAFE strategy been successful?
• The strategy is clear and understandable
• Progress can be measured using the WHO-endorsed simplified grading system to measure trachoma prevalence; this allows comparisons between and within countries
• Regular meetings allow for the exchange of information between programme managers and produce pride in achievements
• Regular meetings between operational researchers and programme managers encourage rapid uptake of new techniques and practices
• Delivery of services (such as eyelid surgery for trichiasis, distribution of antibiotics, latrine promotion) is performed effectively and inexpensively by non-specialists
• The success of each component of the strategy encourages communities to buy-in to other components
• Mass treatment with single-dose oral azithromycin is effective and feasible, and popular with recipient communities
• Azithromycin is well tolerated, relatively free from side-effects and has additional benefits such as being effective against malaria as well as infections of the respiratory tract and skin
• Resistance to azithromycin has not been reported for C. trachomatis
• Azithromycin is donated and shipped to endemic countries by Pfizer • Advocacy for trachoma control by nongovernmental development organizations and WHO has led to increased governmental commitment in some countries
• Nongovernmental development organizations have had strong involvement in trachoma control
• Intersectoral programmes include organizations working on improving water supplies and sanitation in addition to those providing eye care primary function is to prevent transmisd d sion rather than treat trichiasis or infecd d tion. 28 A series of riskdfactor analyses found an association between not having a clean face and an increased individual likelihood of having signs of active trachoma, suggesting that faced washing could reduce the prevalence of trachoma. [29] [30] [31] Formative research in the United Republic of Tanzania sugd d gested that it would indeed be possible to change hygiene practices to increase facial cleanliness and also demonstrated that it was possible to wash many faces with just a small quantity of water. 32, 33 A study in the Gambia showed that members of households that allocated a greater proportion of their water to hygiene had a reduced risk of trachoma compared with those who did not, thus providing additional support to the argument for promoting facedwashing to control trachoma. 34 This evidence led to an RCT of hygiene promotion to control trachoma 35 that -although some of the comparisons narrowly failed to achieve statistical significance -was considered sufficiently compelling by WHO to warrant inclusion as part of the integrated strategy.
Eyedseeking flies have been associated with trachoma for hundreds of years, 28 but flydcontrol was not incorporated into national trachoma plans because there was no evidence that investment in it would have an impact on trachoma transmission. A series of small studies conducted in the Gambia suggested that eyedseeking flies were transmitting trachoma and also identified a putative vector, Musca sorbens, that breeds in human faeces. [36] [37] [38] A larger clusterd randomized controlled trial that tested both fly control with insecticide and the provision of household latrines to reduce the breeding media of M. sorbens in villages confirmed that M. sorbens was a trachoma vector and demonstrated that providing household latrines significantly reduced contact between flies and eyes. 39 The agency that provided the latrines was the same government department that had responsibility for rural sanitation. Participation in the operational research dovetailed with its own targets for latrine provision and helped it exceed its yearly goal. In common with trials of surgery delivery, the active participation of the implementing agencies as equal partners in the operational research ensured that there was no lag in putting research into practise and minimizing the "know-do" gap. Thus, the operational research became a part of practice.
There have been no RCTs studyd d ing the effect of providing water on the prevalence of trachoma, but several studies have shown that families living further from a water source are at greater risk of trachoma than similar families living closer. [40] [41] [42] Trachoma has also been shown to disappear where water has bed d come available, even in the absence of an antibioticdbased control programme. 43, 44 Provision of water sources is a compod d nent of a few national programmes, such as that in Morocco, but the perceived high cost makes it unattainable for most. Improving access to safe drinking water is included in Millennium Development Goal 7, 45 and national programmes are using this goal to ensure that water prod d vision is prioritized for communities where trachoma is endemic.
No trachoma control programme in the world is based solely either on hygiene promotion or environmental change, but operational researchers must investigate their effects individually in order to unequivocally demonstrate efficacy. This necessitates recruiting several communities into trials because the interventions act at the level of the community and not the individual. Cost considerations usually limit the number of communities included in these studd d ies to the minimum allowable, which inevitably leads to studies that have low statistical power to demonstrate an effect in excess of 30% against the comparison group. In the future, trials of facedwashing and the provision of latrines should probably be repeated usd d ing the quantified load of C. trachomatis to determine the scale of the effect with greater precision.
Conclusions
Researchers working on trachoma in the past decade in Ethiopia, the Gambia, Nepal, the United Republic of Tanzania and other endemic countries have worked closely with national eyedcare programmes. Thus, results are availd d able to the programmes as soon as they are generated. A strong international network of personal contacts between those working on trachoma control has developed as a result of meetings of the GET 2020 alliance, the Carter Center programme reviews, and through ind d formal contacts developed through the International Agency for the Prevention of Blindness and the International Cend d tre for Eye Health. A number of national and regional programme managers have taken courses in community ophthalmold d ogy at the International Centre for Eye Health. The centre itself was supported by the International Trachoma Initiative to undertake an independent evaluation of trachoma control programmes in eight countries. These evaluations used a common methodology, developed at a workshop attended by stakeholders from each country, and were conducted in cold d laboration with national programmes by an international team including experts from other endemic countries in the region. Important lessons were learned and disseminated to programme managd d ers in other countries. 46 National programmes reporting at regional and international meetings inspire other programme managers, resulting in the rapid adoption of new approaches. For example, at least nine national trachoma control programmes reported progress towards increasing acd d cess to latrines at the GET 2020 meeting in 2003, 4 even though the peerdreviewed paper demonstrating the association between latrine provision and reduced contact between flies and eyes was not published until the following year.
Similarly, the use of paramedical staff to perform eyelid surgery was rapidly and widely adopted, and the fear that prod d grammes were offering a reduceddquality service was put to rest by independent assessment of the outcome of surgeries, comparing those performed by ophd d thalmologists with those performed by paramedical staff.
In the future it is likely that nad d tional policy on the use of azithromycin will be modified in light of results from studies on the rational use of antibiotics. As the prevalence of signs of trachoma declines, the decision to offer antibiotics may depend on the use of a pointdofd care dipstick to detect whether ocular C. trachomatis is present in the comd d munity.
Combining operational research about trachoma with the implementad d tion of the SAFE strategy offers an example of how to minimize the gap between knowledge and practise and how to put the results of research into policy and planning. O Les résultats de cette recherche ont conduit aux évolutions suivantes : Il est fréquent maintenant que les actes chirurgicaux soient pratiqués par des agents paramédicaux appartenant à la communauté, plutôt que par des ophtalmologistes en milieu hospitalier; la distribution massive pendant un an d'une dose orale unique d'azithromycine a remplacé l'administration de la tétracycline par voie topique et on recourt à la promotion d'une meilleure hygiène, du lavage facial et de l'utilisation des latrines pour réduire la transmission. Les responsables de la mise en oeuvre des programmes sont partenaires à niveau égal de la conduite de la recherche opérationnelle, ce qui diminue le fossé entre savoir et faire et le décalage fréquent entre la réalisation 
Resumen
Estrategia SAFE de control del tracoma: uso de las investigaciones operacionales para la formulación de políticas, la planificación y la implementación
El tracoma es una enfermedad desatendida y la principal causa infecciosa de ceguera a nivel mundial. Provoca miseria y dependencia y constituye un obstáculo para el desarrollo. El tracoma está siendo combatido mediante una estrategia integrada apoyada por la OMS que combina la corrección quirúrgica de la triquiasis, la antibioticoterapia, la higiene facial y las mejoras ambientales (en sus siglas inglesas: SAFE). Esta estrategia, basada en la evidencia obtenida en ensayos sobre el terreno y objeto de continuas mejoras gracias a investigaciones operacionales que orientan las políticas y la planificación nacionales, ha influido en la ejecución de los programas. Como consecuencia de los resultados de las investigaciones operacionales, las intervenciones quirúrgicas son realizadas a menudo por personal paramédico en las comunidades, más que por oftalmólogos en los hospitales; la distribución masiva anual de una sola dosis oral de azitromicina ha reemplazado al uso tópico de tetraciclina; y para reducir la transmisión se fomenta una mayor higiene, el lavado de la cara y el uso de letrinas. Los responsables de la implementación de programas han participado como asociados en condiciones de igualdad en la realización de las investigaciones operacionales, mitigando así la brecha teórico-práctica y reduciendo al mínimo el frecuente desfase entre la finalización de los ensayos y la puesta en práctica de sus resultados. Las investigaciones operacionales se han convertido en parte de la práctica. Aunque quedan todavía muchas preguntas sin respuesta, la confianza de los coordinadores de los programas nacionales en que los programas de control del tracoma basados en la estrategia SAFE funcionarán es una expectativa razonable. 
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